Information letter on ZOFRAN® (ondansetron) and generic medicinal products
2012.08.14
Active substance: ondansetron
The pharmaceutical manufacturer issues information on important new findings regarding ondansetron (ZOFRAN® and generics) and the dose-dependent QTc interval prolongation – new reduction of intravenous dose.
Download DHPC / Information letter , Download_VeroeffentlichtAm_EN